Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Cash from Financing Activities: 2020-2025

Historic Cash from Financing Activities for InMed Pharmaceuticals (INM) over the last 6 years, with Jun 2025 value amounting to $12.3 million.

  • InMed Pharmaceuticals' Cash from Financing Activities fell 116.37% to -$137,178 in Q3 2025 from the same period last year, while for Sep 2025 it was $11.3 million, marking a year-over-year increase of 85.48%. This contributed to the annual value of $12.3 million for FY2025, which is 163.66% up from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Cash from Financing Activities of $12.3 million as of FY2025, which was up 163.66% from $4.7 million recorded in FY2024.
  • Over the past 5 years, InMed Pharmaceuticals' Cash from Financing Activities peaked at $15.1 million during FY2022, and registered a low of $4.7 million during FY2024.
  • In the last 3 years, InMed Pharmaceuticals' Cash from Financing Activities had a median value of $10.7 million in 2023 and averaged $9.2 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first soared by 35,123.14% in 2021, then slumped by 56.42% in 2024.
  • Yearly analysis of 5 years shows InMed Pharmaceuticals' Cash from Financing Activities stood at $10.9 million in 2021, then skyrocketed by 38.84% to $15.1 million in 2022, then declined by 29.13% to $10.7 million in 2023, then plummeted by 56.42% to $4.7 million in 2024, then skyrocketed by 163.66% to $12.3 million in 2025.